Unsustained Response to Benralizumab in Eosinophilic Asthma After 3 Years of Therapy With Mepolizumab

Kurosawa M1, Shimizu Y2, Sutoh Y1, Sutoh E1,3
1Department of Allergy and Respiratory Medicine, Sutoh Hospital, Annaka, Gunma, Japan
2Division of Respiratory Medicine, Kaminakai Family Clinic, Takasaki, Gunma, Japan
3Department of Surgery, Sutoh Hospital, Annaka, Gunma, Japan

doi: 10.18176/jiaci.0652

Key words: Anti-interleukin 5 therapy. Asthma Control Test. Blood eosinophil count. Eosinophilic asthma. FEV1.


Eosinophils play a pivotal role in the inflammatory processes of asthma and have been the target of new biologic treatments for eosinophilic asthma. Benralizumab is the monoclonal antibody that targets the α chain of the interleukin 5 (IL-5) receptor, and mepolizumab is the anti-IL-5 monoclonal antibody. We present the case of a patient with eosinophilic asthma and unsustained response to benralizumab after 3 years of therapy with mepolizumab.

A 42-year-old woman who had never smoked visited the clinic because of increasing dyspnea on January 22, 2016. She was treated with pranlukast 450 mg/d and fluticasone/formoterol 125 µg/5 µg inhaler (2 puffs per day). Because of unstable respiratory symptoms, she was occasionally given systemic corticosteroids. On February 27, 2016, the patient was admitted to hospital by an experienced pulmonologist. We confirmed the diagnosis of asthma using the Global Initiative for Asthma guidelines [1]. Forced expiratory volume in 1 second (FEV1) was 74.1% of predicted, with an increase of 14.1% in FEV1 after salbutamol 180 µg (inhaler). The patient was not allergic. The results of testing indicated a serum total IgE level of 94 IU/mL and negative results in specific IgE for common inhaled allergens including Dermatophagoides farinae and Dermatophagoides pteronyssinus. Her regimen was changed to budesonide/formoterol 160 µg/4.5 µg (8 puffs per day) and montelukast 10 mg/d. She stopped using systemic corticosteroids, and daily use of the inhaler was reduced to 6 puffs per day on April 15.

On June 10, the peripheral blood eosinophil count was 228/µL, and serum total IgE was 155 IU/mL. FEV1 (% predicted) was 75.00%, and the score on the Asthma Control Test (ACT) was 13. The patient agreed to receive the first dose of mepolizumab (100 mg) (Figure). She had no history of poor adherence or comorbidities. On July 9, her blood eosinophil count decreased to 26/µL, while FEV1 and the ACT score were 75.17% and 16. On November 26, the blood eosinophil count, FEV1, and the ACT score were 20/µL, 76.76%, and 25,
and daily use of the inhaler was reduced to 4 puffs per day. On May 11, 2019, FEV$_1$ improved to 79.69%. The fact that she had been administered mepolizumab monthly for 3 years indicated successful long-term management of her asthma. No adverse effects were observed.

Benralizumab can be administered at longer dosing intervals than mepolizumab [2]. Therefore, on May 11, 2019, the patient started benralizumab 30 mg every 4 weeks for the first 3 doses followed by a fixed-dose administration every 8 weeks. She continued to use her inhaler. On July 6, the blood eosinophil count became undetectable. On August 31, she received the fourth dose. Although the blood eosinophil count remained undetectable, she complained of asthma symptoms (the ACT score fell to 21). Physical examination revealed slight wheezing during deep breathing. Adherence to the medication and inhaler technique were deemed adequate. The laboratory data did not reveal respiratory infection. The patient rejected systemic corticosteroids and was given aminophylline. On October 26 and December 21, the blood eosinophil count increased to 335/µL and 413/µL, respectively, and the FEV$_1$ and ACT score fell to 70.97% and 68.01% and 18 and 17. She received aminophylline on both days. On December 21, 2019, she refused to continue benralizumab and instead agreed to receive mepolizumab again every 4 weeks. On January 18, 2020, the blood eosinophil count, FEV$_1$, and ACT score were 281/µL, 71.93%, and 20, and her asthma was gradually controlled. On August 29, 2020, the blood eosinophil count decreased to 30/µL, and the FEV$_1$ and ACT score increased to 79.53% and 25.

The present case of eosinophilic asthma was uncommon. Despite responding to mepolizumab, the patient did not respond to benralizumab. We previously reported that eosinophilic asthma responded to benralizumab after failure to respond to mepolizumab [3], according to the same 3 efficacy endpoints. Blood eosinophil count has been approved as a biomarker for predicting the efficacy of anti–IL-5 therapy in patients with eosinophilic asthma [4] and was therefore main criterion. Based on the guidelines of the UK National Institute for Health and Care Excellence [5], we selected spirometry and lung function as the first 2 parameters to be monitored when determining the response to asthma treatment. As the third, we selected the ACT score [3].

**Figure.** Clinical course of a patient diagnosed with eosinophilic asthma. After initiation of monthly mepolizumab on June 10, 2016 (peripheral blood eosinophil count, 228/µL; FEV$_1$ % predicted, 75.00; and ACT score, 13), the patient’s condition remained controlled for 3 years. On May 11, 2019 (eosinophil count, 50/µL; FEV$_1$; 79.69%; and ACT score, 25), she received benralizumab. Although the blood eosinophil count became undetectable, the pulmonary symptoms worsened (FEV1 and the ACT score dropped to 68.01% and 17). In parallel, the blood eosinophil count increased to 413/µL, indicating an unsustained response to benralizumab. On December 21, 2019, the patient restarted monthly mepolizumab, and her asthma was gradually controlled. On August 29, 2020, the blood eosinophil count decreased to 30/µL, and the FEV$_1$ and the ACT score increased to 79.53% and 25.
The first administration of mepolizumab was followed by a rapid reduction in blood eosinophil count, as reported elsewhere [3]. Reinitiating mepolizumab slowed this reduction. Recent data show secondary loss of response to mepolizumab in 2 patients with eosinophilic asthma after 2 years of treatment [6], in contrast with the present case.

Assessing the efficacy of benralizumab after 5 doses is difficult. The patient refused to continue with the drug and restarted mepolizumab instead. Our findings have 2 potential explanations. First, the BORA phase III extension trial showed that antidrug antibodies to benralizumab were developed by 10% of patients who received therapy every 4 weeks and in 12% who were treated every 8 weeks, with no effect on drug efficacy [7]. Since measurement of antidrug antibody to benralizumab is not available in our laboratory, no clear values could be reported. However, benralizumab has been shown to fully deplete blood eosinophils [8], as we observed. In addition, a sudden rise in the blood eosinophil count with treatment might be used as a biomarker of the development of antibody. Second, it is known that IL-5 is produced not only by CD4+ lymphocytes, but also by type 2 innate lymphoid cells in the airways [9]. Local eosinophilopoiesis may be the predominant process, and after 3 years of therapy with mepolizumab, benralizumab may not have achieved relevant blockade of eosinophilopoiesis [10].

In conclusion, to our knowledge, this is the first case of eosinophilic asthma that responded to mepolizumab, but not to benralizumab. Therefore, based on our previous report of a case where the patient responded to benralizumab after failure to respond to mepolizumab [3], full characterization of eosinophilic asthma is highly recommended for identification of responders to new biologic treatments.

Acknowledgments

The authors thank Junya Maehata, BSc, for assistance in assembling the figure.

Funding

The authors declare that no funding was received for the present study.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References